O EVENTUAL CRIME DE RESPONSABILIDADE PELO PODER EXECUTIVO BRASILEIRO COM A UTILIZAÇÃO DA HIDROXICLOROQUINA NO TRATAMENTO DA COVID-19

Sarah Gonçalves Ribeiro, Luiz Osório Moraes Panza Panza, Guilherme Simas do Amaral Catani Catani

Resumen


O presente artigo destina-se a estudar a possibilidade de o Poder Executivo ter incorrido em crime de responsabilidade, pela imposição do protocolo de tratamento à base de hidroxocloroquina no Brasil. Esse protocolo implantado pelo Ministério da Saúde ampliou as recomendações no uso da droga para as fases iniciais e profiláticas. As considerações, sobre o possível crime, serão feitas a partir das divergências públicas entre as entidades responsáveis pela saúde, em especial a ANVISA. Nesse intento, resolveu-se analisar de forma detalhada a legislação brasileira e estudos científicos, com a finalidade de identificar possíveis transgressões legais. Para isso, utilizou-se método de abordagem comparativa, histórica e científica, para que fosse possível identificar possíveis irregularidades na atuação do Poder Executivo, através do Ministério da Saúde no Brasil. 


Texto completo:

PDF (Português (Brasil))

Referencias


ALEXANDER, P. E. et al. COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. J. Clin. Epidemiol. 123, 120–126 (2020).

AKPOVWA, H. Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity. Cell Biochem. Funct. 34, (2016).

ANDRADE, J. G. de. A randomized clinical trial with high dose of chloroquine for treatment of Plasmodium falciparum malaria in Brazil. Revista do Instituto de Medicina Tropical de Sao Paulo 34, 467–473 (1992).

ASSAD, L. Controvérsias, debates, disputas e farsas: a ciência não é feita por deuses. (2013). Disponível em: . Acesso em: 15 de jun. de 2020.

BANDEIRA DE MELLO, C. A. Curso de Direito Administrativo. 29º ed. São Paulo: Editora Malheiros (2011).

BENTO, L. Crítica ao “consenso” científico. (2008). Disponível em: acesso em: 15 de jun. de 2020.

BHAGAVATHULA, A. S; ALDHALEEI, W. A; ROVETTA, A; RAHMANI, J. Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials. Cureus 12, e8342 (2020).

BORGES, M. C; CASTRO, L. A; FONSECA, B. A. L. da. Chloroquine use improves dengue-related symptoms. Mem. Inst. Oswaldo Cruz 108, (2013).

CARPENTER, A. et al. COVID-19 Management and Arrhythmia: Risks and Challenges for Clinicians Treating Patients Affected by SARS-CoV-2. Front. Cardiovasc. Med. 7, 1–5 (2020).

CHOWDHURY, M. S; RATHOD, J; GERNSHEIMER, J. A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19. Acad. Emerg. Med. 1–12 (2020). doi:10.1111/acem.14005.

COATNEY, G. R. Pitfalls in a discovery: the chronicle of chloroquine. Am. J. Trop. Med. Hyg. 12, 121–128 (1963).

CONANT, J. B. What Is Science? Bull. Natl. Assoc. Second. Sch. Princ. 34, 1950.

CORTEGIANI, A; INGOGLIA, G; IPPOLITO, M; GIARRATANO, A; EINAV, S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J. Crit. Care 57, 279–283, 2020.

COVEN, E. M.; MARINHOS, A. M. C. P. Curso básico em vigilância sanitária. Anvisa - Universidade Federal do Ceará, Fortaleza, 2015, p.08.

DIB, Regina Paolucci El. Fonoaudiologia baseada em evidências e o Centro Cochrane do Brasil. Diagn Trat. 11, (2005).

DOWALL, S. D. et al. Chloroquine inhibited ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. J. Gen. Virol. 96, 3484–3492 (2015).

FISCHER, F. COVID-19 - was wir auf der Intensivstation beachten sollten. Academic.Oup.Com 1–6 (2020). doi:10.1093/cid/ciaa237/5801998.

GAO, J; TIAN, Z; YANG, X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci. Trends 14, 72–73 (2020).

RAOULT, D. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open- label non-randomized clinical trial. IHU-Méditerranée Infection, Marseille, France. Disponível em: https://www.medrxiv.org/content/10.1101/2020.03.16.20037135v1.full.pdf acesso em: 27 de maio de 2020.

GBINIGIE, K; FRIE, K. Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review. BJGP Open bjgpopen20X101069 (2020). doi:10.3399/bjgpopen20x101069

GÉRARD, A. et al. “Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapies (2020). doi:10.1016/j.therap.2020.05.002.

GRECO, R. Curso de Direito Penal. 20º ed. Rio de Janeiro: Editora Impetus, 2018, p.114.

HERNANDEZ, A. V; ROMAN, Y. M; PASUPULETI, V; BARBOZA, J. J; WHITE, C. M. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. Ann. Intern. Med. M20-2496 (2020). doi:10.7326/M20-2496.

HORBY, P; et al. Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. Yale. MedRxiv, 15 de julho de 2020. Disponível em: https://www.medrxiv.org/content/10.1101/2020.07.15.20151852v1.full.pdf+html acesso em: 29 de julho de 2020.

HUANG, X; WEI, F; HU, L; WEN, L; CHEN, K. Epidemiology and clinical characteristics of COVID-19. Arch. Iran. Med. 23, (2020).

JANKELSON, L; KARAM, G; BECKER, M. L; Chinitz, L. A; TSAI, M.C. QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review. Hear. Rhythm (2020). doi:10.1016/j.hrthm.2020.05.008

KANG, J. E; RHIE, S. J. Practice considerations on the use of investigational anti-COVID-19 medications: Dosage, administration and monitoring. J. Clin. Pharm. Ther. n/a, 1–7 (2020).

KELLAND, K; SMOUT, A. UK halts trial of hydroxychloroquine as 'useless' for COVID-19 patients. Thomas Reuters, 5 de junho de 2020. Disponível em: https://www.reuters.com/article/us-health-coronavirus-hydroxychloroquine-idUSKBN23C1YM acesso em: 29 de julho de 2020.

KUMAR, A; SINGH, A; SHAIKH, A; SINGH, R. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab. Syndr. Clin. Res. Rev. 14, 241–246 (2020).

LI, C. et al. Chloroquine, a FDA-approved Drug, Prevents Zika Virus Infection and its Associated Congenital Microcephaly in Mice. EBioMedicine 24, 189–194 (2017).

LIU, W. et al. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARSCoV-2 and other acute viral infections: a systematic review and meta-analysis. CMAJ 1–11 (2020). doi:10.1503/cmaj.200647

LOPES, A. A. Medicina Baseada em Evidências: a arte de aplicar o conhecimento científico na prática clínica. Rev. Assoc. Med. Bras. 46, (2000).

MARCO T. MEDINA, C; MONCADA, S. S. Hydroxychloroquine/ chloroquine as a treatment choice or prophylaxis for Covid-19 at the primary care level in developing countries: A Primum non Nocere dilemma. J. Neurol. Sci. 415, 116972 (2020).

MAZUMDER, A. et al. SARS-CoV-2 epidemic in India: epidemiological features and in silico analysis of the effect of interventions. F1000Research 9, 315 (2020).

MEHRA, M. R; DESAI, S. S; RUSCHIZKA, F; PATEL, A. N. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet, 22 de maio de 2020. Disponível em: https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)31180-6.pdf acesso em: 27 de maio de 2020.

MEHRA, M. R; DESAI, S. S; RUSCHITZKA, F; PATEL, A. N. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet (London, England) (2020). doi:10.1016/S0140-6736(20)31180-6

MEO, S. A; KLONOFF, D. C; AKRAM, J. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. Eur. Rev. Med. Pharmacol. Sci. 24, 4539–4547 (2020).

MONTESQUIEU. O espírito das leis. São Paulo: Editora Martins Fontes, 2000.

MITJÀ, Oriol et al. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial. Oxford University Press. 16 jul. 2020 Disponível em: https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa1009/5872589 acesso em: 29 de jul. de 2020,

NAKSUK, N; LAZAR, S; PEERAPHATDIT, T. B. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. Eur. Hear. journal. Acute Cardiovasc. care 1–7 (2020). doi:10.1177/2048872620922784.

PATIL, V. M; SINGHAL, S; MASAND, N. A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials. Life Sci. 254, (2020).

PATON, N. I; ABOULHAB, J. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: Safety, efficacy and resistance profile after 144 weeks. HIV Med. 6, 13–20 (2005).

RODRIGO, C., FERNANDO, S. D; RAJAPAKSER, S. Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review. Clin. Microbiol. Infect. (2020). doi:10.1016/j.cmi.2020.05.016

ROQUES, P. et al. Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection. Viruses 10, 1–18 (2018).

RUIZ-IRASTORZA, G; RAMOS-CASALS, M; BRITO-ZERON, P; KHAMASHT, M. A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann. Rheum. Dis. 69, 20–28 (2010).

SHAH, S; DAS, S; JAIN, A; MISRA, D. P; NEGI, V. S. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). Int. J. Rheum. Dis. 613–619 (2020). doi:10.1111/1756-185X.13842

SHIRYAEV, S. A. et al. Repurposing of the anti-malaria drug chloroquine for Zika Virus treatment and prophylaxis. Sci. Rep. 7, 1–9 (2017).

SHUKLA, A. M; ARCHIBALD, L. K; WAGLE SHUKLA, A; MEHTA, H. J; CHERABUDDI K. Chloroquine and hydroxychloroquine in the context of COVID-19. Drugs Context 9, 1–8 (2020).

SIMÕES, E. Ex-chefe da Anvisa alerta para riscos de cloroquina contra Covid-19; diz que protocolo é "barbaridade”. Reuters, 20 de maio de 2020. Disponível em: https://br.reuters.com/article/idBRKBN22W2YS-OBRTP acesso em: 26 de maio de 2020.

SKIPPER, MD et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. 16 jun. 2020. Disponível em: https://www.acpjournals.org/doi/10.7326/M20-4207 acesso em 28 de julho de 2020.

TRIPAYHY, S; DASSARMA, B; ROY, S; CHABALALA, H; MATSABISA, M. G. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic. Int. J. Antimicrob. Agents 2, (2020).

VINCENT, M. J. et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J. 2, 1–10 (2005).

WANG, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, (2020).

WANG, L. F. et al. Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery. J. Interf. Cytokine Res. 35, (2015).

WENIGER, H; ORGANIZATION, W. H. Review of side effects and toxicity of chloroquine / by H. Weniger. (Geneva : World health Organization, 1979).

WITTES, R. Adverse reactions to chloroquine and amodiaquine as used for malaria prophylaxis: a review of the literature. Can. Fam. Physician 33, (1987).

YAN, Y. et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res. 23, 300–302 (2013).

YAO, X. et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Main point : Hydroxychloroquine was found to be more potent than chloroquine at inhibiting SARS-CoV-2 in vit. Clin. Infect. Dis. 2, 1–25 (2020).


Enlaces refback

  • No hay ningún enlace refback.


Copyright (c) 2020 Cadernos de Dereito Actual

Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.


 

Cadernos de Dereito Actual

www.cadernosdedereitoactual.es

© 2013 por Xuristas en Acción.  

ISSN impreso: 2340-860X. ISSN electrónico: 2386-5229

 

Indexada en | Indexed by:

 

 

Consulta más bases de datos aquí